Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Athersys, a biopharmaceutical company, has completed patient enrollment for its Phase I study of MultiStem for Hematopoietic Stem Cell Transplant Support in patients being treated for leukemia or other blood born cancers.
Subscribe to our email newsletter
MultiStem, administered intravenously, is an allogeneic cell therapy product candidate which helps promote healing and tissue repair.
The Phase I multi-center dose escalation clinical trial is intended to assess the safety and tolerability of a single or repeat dose administration of allogeneic MultiStem delivered intravenously following a traditional donor-derived hematopoietic stem cell transplant.
The patients received either a low, medium or high dose of MultiStem for both the single and repeat dose arms.
The data is likely to be announced at the end of the year.